WO2025261470 - SULFONYL COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/261470
Publication Date
26.12.2025
International Application No.
PCT/CN2025/102281
International Filing Date
20.06.2025
Title **
[English]
SULFONYL COMPOUND AND USE THEREOF
[French]
COMPOSÉ SULFONYLE ET SON UTILISATION
[Chinese]
磺酰类化合物及其应用
Applicants **
NANJING ZAIMING PHARMACEUTICAL CO., LTD.
Inventors
ZHOU, Muxing
WANG, Juan
YANG, Yang
WANG, Weikun
YANG, Guimei
CHEN, Yue
MENG, Xiaoqing
LIU, Yajing
YU, Jian
LI, Zhengtao
TANG, Renhong
Priority Data
202410812439.8
21.06.2024
CN
202411083299.1
08.08.2024
CN
202411385352.3
30.09.2024
CN
202510050856.8
13.01.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2119 | |
| EPO | Filing, Examination, Granting | 14882 | |
| Japan | Filing, Examination, Granting | 2340 | |
| South Korea | Filing, Examination, Granting | 2634 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
26,915
Contact Us
Abstract[English]
Provided in the present disclosure are a sulfonyl compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a pharmaceutical composition containing same, and the use thereof as a WRN inhibitor in the prevention or treatment of related diseases.[French]
La présente invention concerne un composé sulfonyle tel que représenté dans la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci ou un stéréoisomère de celui-ci, une composition pharmaceutique le contenant, et son utilisation en tant qu'inhibiteur de WRN dans la prévention ou le traitement de maladies associées.[Chinese]
本公开提供了一种式(I)所示的磺酰类化合物或其药学可接受的盐或其立体异构体，含有它们的药物组合物以及其作为WRN抑制剂在预防或治疗相关疾病中的应用。